Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29306513.
- Also identified by DOI 10.1016/j.eururo.2017.12.021.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In men with prostate-specific antigen failure after radical radiotherapy, androgen deprivation therapy should be delayed until the site of recurrence is known to allow consideration of curative treatment options, to delay androgen deprivation therapy-related morbidity, and to enable earlier access to abiraterone and docetaxel.
Medical subject headings
- Androgen Antagonists
- Neoplasm Metastasis
- Prostate-Specific Antigen
- Prostatectomy
- Prostatic Neoplasms
- Quality of Life
- Radiotherapy
- Time-to-Treatment